Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697

Agarwal,Vijay; Hodgkinson,Victoria  C.; Eagle,Gina  L.; Scaife,Lucy; Lind,Michael  J.; Cawkwell,Lynn

doi:10.3892/ijo.2013.1784

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697

Authors:
- Vijay Agarwal
- Victoria C. Hodgkinson
- Gina L. Eagle
- Lucy Scaife
- Michael J. Lind
- Lynn Cawkwell
View Affiliations

Affiliations: Cancer Biology Proteomics Group, Postgraduate Medical Institute of the University of Hull, Hull, UK
Published online on: January 22, 2013 https://doi.org/10.3892/ijo.2013.1784
Pages: 1088-1092

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of action of this agent. COX-2-positive cell lines MSTO-211H (mesothelioma) and A549 (lung cancer) were exposed to DuP 697 for 72 h. Drug carrier only was added to control cells. Extracted proteins from treated and control cells were analysed using a comparative proteomic platform. Differentially expressed proteins, identified by the Panorama Xpress Profiler725 antibody microarray were submitted to Ingenuity Pathway Analysis. A total of 32 unique differentially expressed proteins were identified with a significant (>1.8-fold) difference in expression between treated and untreated cells in at least one cell line. Five molecules, BCL2L1 (Bcl-xL), BID, CHUK (IKK), FASLG and RAF1, were mapped to the Apoptosis Signaling pathway following Ingenuity Pathway Analysis. BCL2L1 (Bcl-xL) and BID were analysed using immunoblotting and differential expression was confirmed. Proteomic (antibody microarray) analysis suggests that the mechanism of action of DuP 697 may be exerted via the induction of apoptosis. The antibody microarray platform can be utilised to explore the molecular mechanism of action of novel anticancer agents.

View Figures

View References

1	Hull MA: Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer. 41:1854–1863. 2005. View Article : Google Scholar : PubMed/NCBI
2	Gasparini G, Longo R, Sarmiento R and Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 4:605–615. 2003. View Article : Google Scholar : PubMed/NCBI
3	Rao P and Knaus E: Evolution of nonsteroidal antiinflammatory drugs (NSAIDS): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 11:81S–110S. 2008.PubMed/NCBI
4	Ghosh N, Chaki R, Mandal V and Mandal SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 62:233–244. 2010. View Article : Google Scholar : PubMed/NCBI
5	Menter DG, Schilsky RL and DuBois RN: Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 16:1384–1390. 2010. View Article : Google Scholar : PubMed/NCBI
6	Baldi A, Santini D, Vasaturo F, et al: Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 59:428–433. 2004. View Article : Google Scholar : PubMed/NCBI
7	Edwards JG, Faux SP, Plummer SM, et al: Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res. 8:1857–1862. 2002.PubMed/NCBI
8	Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC and Gerwin BI: Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 60:3696–3700. 2000.
9	Cardillo I, Spugnini EP, Verdina A, Galati R, Citro G and Baldi A: Cox and mesothelioma: an overview. Histol Histopathol. 20:1267–1274. 2005.PubMed/NCBI
10	O’Kane SL, Cawkwell L, Campbell A and Lind MJ: Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer. 41:1645–1648. 2005.PubMed/NCBI
11	Catalano A, Graciotti L, Rinaldi L, et al: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer. 109:322–328. 2004. View Article : Google Scholar : PubMed/NCBI
12	O’Kane SL, Eagle GL, Greenman J, Lind MJ and Cawkwell L: COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer. 67:160–165. 2010.PubMed/NCBI
13	Blobaum AL and Marnett LJ: Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 50:1425–1441. 2007. View Article : Google Scholar : PubMed/NCBI
14	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
15	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
16	Churchman A, Baydoun AR and Hoffman R: Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697). Eur J Pharmacol. 573:176–183. 2007. View Article : Google Scholar
17	Peng HL, Zhang GS, Liu JH, Gong FJ and Li RJ: Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol. 87:121–129. 2008. View Article : Google Scholar : PubMed/NCBI
18	Hodgkinson VC, Elfadl D, Drew PJ, Lind MJ and Cawkwell L: Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. J Proteomics. 74:698–703. 2011. View Article : Google Scholar
19	Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 13:7254–7263. 2007. View Article : Google Scholar : PubMed/NCBI
20	Song G, Chen G, Hu T and Lai PB: Bid stands at the crossroad of stress-response pathways. Curr Cancer Drug Targets. 10:584–592. 2010. View Article : Google Scholar : PubMed/NCBI
21	Strasser A, Cory S and Adams JM: Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30:3667–3683. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kern MA, Haugg AM, Koch AF, et al: Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 66:7059–7066. 2006. View Article : Google Scholar : PubMed/NCBI
23	Lou J, Fatima N, Xiao Z, et al: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev. 15:1598–1606. 2006. View Article : Google Scholar
24	Pang RP, Zhou JG, Zeng ZR, et al: Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett. 251:268–277. 2007. View Article : Google Scholar : PubMed/NCBI
25	Schonthal AH: Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 97:1465–1468. 2007. View Article : Google Scholar : PubMed/NCBI